Evidence map›Paper›PMID 36432705›Full record

ReviewPharmaceutics2022

Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson's Disease.

Alexander V Blagov, Andrey G Goncharov, Olga O Babich, Viktoriya V Larina, Alexander N Orekhov, Alexandra A Melnichenko

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Mitochondrial dysfunction in neurodegenerative disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alexander V BlagovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315 Moscow, Russia.
Andrey G GoncharovCenter for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, 6 Gaidara Street, 236001 Kaliningrad, Russia.
Olga O BabichScientific and Educational Center for Industrial Biotechnology, Immanuel Kant Baltic Federal University, 2 Universitetskaya Street, 236040 Kaliningrad, Russia.ORCID 0000-0002-4921-8997
Viktoriya V LarinaScientific and Educational Center for Industrial Biotechnology, Immanuel Kant Baltic Federal University, 2 Universitetskaya Street, 236040 Kaliningrad, Russia.
Alexander N OrekhovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315 Moscow, Russia.ORCID 0000-0002-3318-4681
Alexandra A MelnichenkoLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315 Moscow, Russia.
Immanuel Kant Baltic Federal University · RUResearch Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RU

Funding

Russian Science Foundation 22-65-00005
6 · The paper itself

Abstract

Impaired mitophagy is one of the hallmarks of the pathogenesis of Parkinson's disease, which highlights the importance of the proper functioning of mitochondria, as well as the processes of mitochondrial dynamics for the functioning of dopaminergic neurons. At the same time, the main factors leading to disruption of mitophagy in Parkinson's disease are mutations in the Pink1 and Parkin enzymes. Based on the characterized mutant forms, the marked cellular localization, and the level of expression in neurons, these proteins can be considered promising targets for the development of drugs for Parkinson's therapy. This review will consider such class of drug compounds as mitophagy activators and these drugs in the treatment of Parkinson's disease.

Indexed as

mitochondriamitophagyParkinson’s disease

Identifiers

PMID36432705
PMCPMC9696222
OpenAlexW4309737309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.